BioSpace News Archive

The vendor landscape in the global dental prosthetics market demonstrates a relatively consolidated structure, states a new report by Transparency Market Research (TMR).

Transparency Market Research has published a new report titled, “Global Periodontal Therapeutics Market”. According to the report, the global periodontal therapeutics market was valued at US$ 537.0 Mn in 2018 and is projected to expand at a CAGR of 8.8% from 2019 to 2027.

Ibere Pharmaceuticals (NYSE: IBER) (the “Company”) today announced that it received a notice on May 25, 2021 from the New York Stock Exchange (the “NYSE”) indicating that the Company is not in compliance with Section 802.01E of the NYSE Listed Company Manual as a result of its failure to timely file its Quarterly Report

Werewolf Therapeutics, Inc., an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, announced the appointment of Mike Sherman, chief executive officer of Chimerix, Inc., as a member of its board of directors.

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery platform to develop a novel class of orally administered biological drugs, announced that Mark Smith, PhD, Chief Executive Officer, will participate in two upcoming virtual investor conferences:

Online event to include a live reading by Children’s Author, Ariana Feiner, whose short film documentary, A Story of Courage, has won 24 international awards

SOFIE, an established Radiopharmaceutical Contract Manufacturing Organization and GMP radiopharmacy network, will be commercially manufacturing and distributing PYLARIFY® injection, an F 18-labeled prostate-specific membrane antigen targeted positron emission tomography imaging agent.

Spectrum Pharmaceuticals, a biopharmaceutical company focused on novel and targeted oncology therapies, announced a poster presentation on poziotinib CNS activity in patients with NSCLC with EGFR or HER2 exon 20 mutations.

Cybin Inc., a biotechnology company focused on progressing psychedelic therapeutics, announced that Doug Drysdale, Chief Executive Officer, will be presenting at the Jefferies Virtual Healthcare Conference 2021.

180 Life Sciences Corp. (NASDAQ: ATNF) (180 Life Sciences or the “Company”), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced that it has appointed Russell T. Ray, MBA and Teresa DeLuca MD, MBA to its Board of Directors (“Board”) effective June 15, 2021.